A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany (LUNET-2)

June 12, 2026 updated by: Novartis Pharmaceuticals

Use of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumour (NET) Patients in Germany - A Retrospective Evaluation in German Centers for NET (LUNET-2 Study)

The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

117

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Essen, Germany
        • Novartis Investigative Site
      • Heidelberg, Germany
        • Novartis Investigative Site
      • München, Germany
        • Novartis Investigative Site
      • Rostock, Germany
        • Novartis Investigative Site
      • Stuttgart, Germany
        • Novartis Investigative Site
      • Tübingen, Germany
        • Novartis Investigative Site
      • Würzburg, Germany
        • Novartis Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult GEP-NET patients in Germany who received their first cycle of primary PRRT between 01 July 2020 and 30 June 2021.

Description

Inclusion criteria:

  • Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin [CUP], any Grade).
  • Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021.

Exclusion criteria:

  • Received a combination of PRRT with chemotherapy.
  • Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
PRRT Cohort
Adult GEP-NET patients who received PRRT in German routine care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Baseline Demographics
Time Frame: Baseline
Baseline
Number of Patients by Tumor Status
Time Frame: Baseline
Baseline
Duration Between Initial Diagnosis and Initiation of Primary PRRT
Time Frame: Baseline
Baseline
Number of Patients by PRRT Line of Therapy
Time Frame: Approximately 1 year
Approximately 1 year
Number of Patients by Type of PRRT Received
Time Frame: Approximately 1 year
Approximately 1 year
PRRT Dosage
Time Frame: Approximately 1 year
Approximately 1 year
Number of Patients by Treatment Interval
Time Frame: Approximately 1 year
Approximately 1 year
Number of Patients by Co-medication
Time Frame: Approximately 1 year
Approximately 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 3, 2023

Primary Completion (Actual)

September 29, 2023

Study Completion (Actual)

September 29, 2023

Study Registration Dates

First Submitted

June 12, 2026

First Submitted That Met QC Criteria

June 12, 2026

First Posted (Actual)

June 17, 2026

Study Record Updates

Last Update Posted (Actual)

June 17, 2026

Last Update Submitted That Met QC Criteria

June 12, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAAA601A1DE01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastro-enteropancreatic Neuroendocrine Tumor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe